This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these messages)
|
P. Eline Slagboom | |
---|---|
Born | Dordrecht, Netherlands | January 14, 1960
Nationality | Dutch |
Alma mater | Leiden University |
Scientific career | |
Fields | Molecular Epidemiology, human genetics, ageing, longevity, complex diseases, epigenetics |
Institutions | Leiden University Medical Center |
Website | www.molepi.nl |
P. Eline Slagboom (born January 18, 1960, Dordrecht, the Netherlands) is a Dutch biologist specializing in the human familial longevity and ageing.
Slagboom attended Christelijk Lyceum in Delft, graduating in 1978, before continuing to Leiden University for her Bachelors (1979) and Masters (1985) degrees in biology, followed by a Ph.D. focusing on Genomic Instability and Aging (1993) from the same institution.
After receiving her Ph.D., Slagboom joined the Department of Vascular and Connective Tissues Research at the Gaubius Laboratory (TNO-PG, the Netherlands). As a post doc she initiated a unit for genetic epidemiological studies aimed at the identification of genetic determinants of multifactorial diseases. Slagboom started between 1995 and 1997 a genetic research line on osteoarthritis (OA) including linkage studies in families with early onset OA, genetic association studies in population cohorts and linkage studies in populations of affected sibling-pairs. From 1998 on, Slagboom, in collaboration with research groups at different universities, obtained various grants that allowed initiation of a genotyping facility for genome scanning at the Netherlands Organisation for Applied Scientific Research (TNO). In 2000, Slagboom was appointed as professor of molecular epidemiology at the Leiden University Medical Center. [1] She established a new section of Molecular Epidemiology and Genotyping Center at the department of Medical Statistics and Bioinformatics. Slagboom has initiated a masterclass for Statistical Analysis of Genetic Data and Bioinformatics in Genomic Research and is involved in various teaching activities.
Focus of the research in the past 10 years is on genomic, epigenetic and biomarker studies of healthy/unhealthy ageing and familial longevity in humans. These studies include genomics, metabolomics, and proteomics analysis of age-related disease. A diversity of human cohorts with unique study designs is being analysed for this purpose. Slagboom is one of two founders of the Research on Ageing at the Leiden University Medical Center, supported among other foundations by the Netherlands Genomic Initiative. She initiated and heads the Leiden Longevity Study (LLS) together with R.G.J. Westendorp and a research cohort of osteoarthritis patients. The mission of her research group is the identification of genomic factors, biomarkers, and functional mechanisms marking and contributing to complex diseases in humans with a focus on ageing, longevity, and age-related disease. Slagboom has a leading role in large consortia within ageing research such as the Netherlands Consortium on Healthy Ageing, in which she established collaborative research with industry, and European Union large scale collaborative research projects (Treat~OA, GEHA, and LIFESPAN).
Currently she heads a group of 15–20 scientists and academic staff has now started to obtain grants for new research lines (functional genomic studies in osteoarthritis and studies into interaction between genetic and epigenetic variation). She is PI of a new large scale collaborative FP7 project (IDEAL: Integrated research on DEvelopmental determinants of Ageing and Longevity) together with Bas Zwaan (Wageningen University and Research Centre; 2011–2016). [2]
Senescence or biological aging is the gradual deterioration of functional characteristics in living organisms. Whole organism senescence involves an increase in death rates or a decrease in fecundity with increasing age, at least in the later part of an organism's life cycle. However, the resulting effects of senescence can be delayed. The 1934 discovery that calorie restriction can extend lifespans by 50% in rats, the existence of species having negligible senescence, and the existence of potentially immortal organisms such as members of the genus Hydra have motivated research into delaying senescence and thus age-related diseases. Rare human mutations can cause accelerated aging diseases.
Penetrance in genetics is the proportion of individuals carrying a particular variant of a gene (genotype) that also expresses an associated trait (phenotype). In medical genetics, the penetrance of a disease-causing mutation is the proportion of individuals with the mutation that exhibit clinical symptoms among all individuals with such mutation. For example: If a mutation in the gene responsible for a particular autosomal dominant disorder has 95% penetrance, then 95% of those with the mutation will go on to develop the disease, showing its phenotype, whereas 5% will not.
Life extension is the concept of extending the human lifespan, either modestly through improvements in medicine or dramatically by increasing the maximum lifespan beyond its generally-settled biological limit of around 125 years. Several researchers in the area, along with "life extensionists", "immortalists", or "longevists", postulate that future breakthroughs in tissue rejuvenation, stem cells, regenerative medicine, molecular repair, gene therapy, pharmaceuticals, and organ replacement will eventually enable humans to have indefinite lifespans through complete rejuvenation to a healthy youthful condition (agerasia). The ethical ramifications, if life extension becomes a possibility, are debated by bioethicists.
A supercentenarian, sometimes hyphenated as super-centenarian, is a person who is 110 years or older. This age is achieved by about one in 1,000 centenarians. Supercentenarians typically live a life free of significant age-related diseases until shortly before the maximum human lifespan is reached.
Nutritional genomics, also known as nutrigenomics, is a science studying the relationship between human genome, human nutrition and health. People in the field work toward developing an understanding of how the whole body responds to a food via systems biology, as well as single gene/single food compound relationships. Nutritional genomics or Nutrigenomics is the relation between food and inherited genes, it was first expressed in 2001.
Personalized medicine, also referred to as precision medicine, is a medical model that separates people into different groups—with medical decisions, practices, interventions and/or products being tailored to the individual patient based on their predicted response or risk of disease. The terms personalized medicine, precision medicine, stratified medicine and P4 medicine are used interchangeably to describe this concept, though some authors and organizations differentiate between these expressions based on particular nuances. P4 is short for "predictive, preventive, personalized and participatory".
Avesthagen Limited is an integrated systems biology platform company headquartered in Bangalore, India. It was founded as an academic startup in 1998 by Villoo Morawala-Patell, a Rockefeller Fellow and grantee within NCBS-UAS, Bangalore. Avesthagen started business operations on March 21, 2001 with Series-A round investment led by ICICI Ventures and Tata Industries. Villoo Morawala Patell, is the Chairperson and Managing Director of Avesthagen Limited.
The following outline is provided as an overview of and topical guide to life extension:
In genomics, a genome-wide association study, is an observational study of a genome-wide set of genetic variants in different individuals to see if any variant is associated with a trait. GWA studies typically focus on associations between single-nucleotide polymorphisms (SNPs) and traits like major human diseases, but can equally be applied to any other genetic variants and any other organisms.
Computational epigenetics uses statistical methods and mathematical modelling in epigenetic research. Due to the recent explosion of epigenome datasets, computational methods play an increasing role in all areas of epigenetic research.
Ageing is the process of becoming older. The term refers mainly to humans, many other animals, and fungi, whereas for example, bacteria, perennial plants and some simple animals are potentially biologically immortal. In a broader sense, ageing can refer to single cells within an organism which have ceased dividing, or to the population of a species.
Genotype to Phenotype Databases: a Holistic Approach (GEN2PHEN) is a European project aiming to develop a knowledge web portal integrating information from the genotype to the phenotype in a unifying portal: The Knowledge Centre].
The Genomic Medicine Institute at the Cleveland Clinic is an inter-disciplinary institute and department that focuses on patient care, patient-oriented research, and outreach and education in personalized healthcare guided by genetics and genomics. It is located in the Center for Genomics Research Building in the Cleveland Clinic, in Cleveland, Ohio, United States of America.
GeneNetwork is a combined database and open-source bioinformatics data analysis software resource for systems genetics. This resource is used to study gene regulatory networks that link DNA sequence differences to corresponding differences in gene and protein expression and to variation in traits such as health and disease risk. Data sets in GeneNetwork are typically made up of large collections of genotypes and phenotypes from groups of individuals, including humans, strains of mice and rats, and organisms as diverse as Drosophila melanogaster, Arabidopsis thaliana, and barley. The inclusion of genotypes makes it practical to carry out web-based gene mapping to discover those regions of genomes that contribute to differences among individuals in mRNA, protein, and metabolite levels, as well as differences in cell function, anatomy, physiology, and behavior.
Biomarkers of aging are biomarkers that could predict functional capacity at some later age better than chronological age. Stated another way, biomarkers of aging would give the true "biological age", which may be different from the chronological age.
The National Institute of Genomic Medicine is one of Mexico's twelve national institutes under the Secretariat of Health. The institute was founded in 2004, with its official headquarters built eight years later. INMEGEN is dedicated to the development of genomic medicine for the Mexican population. The institute carried out research projects aim to improve healthcare through prevention and medical care related to oncogenomics, nutrigenomics and pharmacogenomics. INMEGEN also studies metabolic, cardiovascular, autoimmune and infectious diseases. INMEGEN collaborates with other Mexican and international institutions for the development of different projects. The current director of the institution is Francisco Xavier Soberón.
Nir Barzilai is an Israeli geneticist and longevity researcher.
An epigenome-wide association study (EWAS) is an examination of a genome-wide set of quantifiable epigenetic marks, such as DNA methylation, in different individuals to derive associations between epigenetic variation and a particular identifiable phenotype/trait. When patterns change such as DNA methylation at specific loci, discriminating the phenotypically affected cases from control individuals, this is considered an indication that epigenetic perturbation has taken place that is associated, causally or consequentially, with the phenotype.
Steve Horvath is a German–American aging researcher, geneticist, and biostatistician. He is a professor at the University of California, Los Angeles known for developing the Horvath aging clock, which is a highly accurate molecular biomarker of aging, and for developing weighted correlation network analysis. His work on the genomic biomarkers of aging, the aging process, and many age related diseases/conditions has earned him several research awards. Horvath is a principal investigator at the anti-aging startup Altos Labs and co-founder of nonprofit Clock Foundation.
Nicole Soranzo is an Italian-British senior group leader in human genetics at the Wellcome Sanger Institute, Professor of Human Genetics at the University of Cambridge. She is an internationally recognised Human Geneticist who has focused on the application of cutting edge genomic technologies to study the spectrum of human genetic variation associated with cardio-metabolic and immune diseases. She has led many large-scale discovery efforts including more than 1,000 novel genetic variants associated with cardio-metabolic diseases and their risk factors as well as establishing the HaemGen consortium, which is a worldwide effort to discover genetic determinants of blood cell formation and also interpretation of the downstream consequences of sequence variation through a host of integrative analyses and functional approaches.